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Objectives: This study aimed to assess the role of OST-α, OST-β and NTCP in patients with 
ICP, with a view to determine patients with severe prognosis and to minimize adverse fetal 
outcomes.  
Material and methods: Sixty-nine pregnant women diagnosed with ICP and 50 healthy 
women were included the study. Serum OST-α, OST-β and NTCP were measured using 
ELISA kits.  
Results: The median OST-α levels were 176.3 pg/mL in women with ICP and 201 pg/mL in 
healthy subjects (p = 0.205). The median OST-β levels were found to be 51.17 pg/mL in 
 
 
patients with ICP and 40.9 pg/mL in controls (p = 0.033). Median NTCP levels were 519.7 
ng/mL in the ICP group and 483.3 ng/mL in healthy women (p = 0.051).  
Conclusions: This is the first study to evaluate serum levels of OST-α, OST-β and NTCP in 
patients with ICP. It is likely that OST-α, OST-β and NTCP contribute to the etiopathogenesis 
of ICP. Serum OST-α and OST-β levels can be used as diagnostic and monitoring markers of 
ICP, and the inhibition of these molecules could provide therapeutic benefit in ICP by 
reducing the circulation of enterohepatic bile acids.  
Key words: bile acids; intrahepatic cholestasis of pregnancy; organic solute transporter 
alpha/beta; sodium taurocholate cotransporting polypeptide 
 
INTRODUCTION 
Intrahepatic cholestasis of pregnancy (ICP) is the most common pregnancy-specific 
liver disease characterized by elevated serum bile acids, maternal pruritus in the second half 
of pregnancy, and an increased rate of adverse fetal outcomes, including intrapartum fetal 
distress, spontaneous preterm delivery, meconium staining of the amniotic fluid, and even 
stillbirths or intrauterine fetal death [1]. Although maternal prognosis is excellent, the risk of 
complications to the fetus and its development increases in parallel with maternal blood levels 
of total bile acids (TBA) [2]. After delivery, the symptoms and biochemical abnormalities 
usually resolve rapidly — almost spontaneously. The incidence of ICP is estimated to range 
between 1% and 4%, but varies greatly depending on environmental factors, ethnic origin and 
genetic predisposition [3]. The etiopathogenesis of the disease is not fully understood, but is 
probably multifactorial with genetic, environmental, dietary and hormonal backgrounds that 
also effect its severity [4]. The impairment of the transport, excretion and function of bile 
acids may be associated with the development of ICP.  
Organic solute transporter alpha/beta (OST-α/OST-β) are solute carrier proteins that 
were identified in the hepatocyte and intestinal epithelium. These heteromeric transporters, 
which are located in basolateral membranes, are critical in the reabsorption and enterohepatic 
circulation of steroid-based molecules, particularly bile acids [5]. Furthermore, it was shown 
in a mice study that the functions of OST-α and OST-β include the protection of the ileal 
epithelium against the accumulation of bile acids [6]. The expression of OST-α and OST-β 
proteins were found to be altered in conditions that cause elevation in bile acids, including 
extrahepatic cholestasis, primary biliary cholangitis and nonalcoholic steatohepatitis [5]. 
However, to our knowledge, there are no studies that have investigated serum levels of OST-
α/OST-β in patients with ICP. 
 
 
Sodium taurocholate cotransporting polypeptide (NTCP) is another transport protein 
localized in the basolateral membrane of the hepatocyte. Its primary function is to collect 
conjugated bile salts from the circulation via cotransport of sodium [7]. NTCP has extremely 
high affinity and specificity for bile acids, and is reported to recover up to 90% from the 
circulation [3]. The gene encoding for NTCP (Solute Carrier Family 10 Member 1, 
SLC10A1) has been shown to have biallelic mutations that impair NTCP function; 
subsequently leading to increased serum levels of TBA [8]. In a recent case study including 
two women who had suffered from ICP, researchers found that homozygote mutations of 
SLC10A1 can lead to ICP development [7]. To date, the results of studies examining the role 
of NTCP in ICP patients remain rather limited. However, no studies have examined the serum 
levels of NTCP in ICP patients. 
The aim of this study was to evaluate the serum levels of OST-α/OST-β and NCPT in 
patients with ICP with a view to identify whether they can be associated with disease 
development and/or severity.  
 
MATERIAL AND METHODS 
This was a prospective single center study that was carried out between July 2020 and 
September 2020 at the Maternal-Fetal Medicine Unit of Health Sciences University Kanuni 
Sultan Suleyman Research and Training Hospital, Istanbul, Turkey. A total of 69 pregnant 
women diagnosed with ICP and 50 healthy women with completely normal pregnancies (as 
the control group) in the third trimester were included in the study. The diagnosis of ICP was 
based on the following criteria: (i) presence of pruritus that cannot be explained with any 
other condition, (ii) elevated levels of serum aminotransferase (> 40 IU/L) and (iii) elevated 
levels of serum fasting TBA (> 10 μmol/L). ICP severity was defined according to TBA 
levels as: mild (10–40 μmol/L) and severe (> 40 μmol/L). Participants with a history of 
conditions that cause abnormalities in liver function tests, including hepatitis, gallstones or 
gallbladder diseases, acute fatty liver of pregnancy, hepatotoxic drug consumption, primary 
biliary cholangitis, primary sclerosing cholangitis, active infection and chronic inflammatory 
conditions, were excluded from the study. Additionally, patients with gestational diabetes, 
preeclampsia, gestational thyroid disorders, malignancy, thrombophilia, those who had 
pruritus with normal bile acids, and those with skin lesions were excluded. 
Gestational age was calculated according to last menstruation date and first trimester 
obstetric radiologic examination. Each ICP patient completed a questionnaire rating the 
severity of pruritus on a numerical scale from 1 to 10. Scores ranging from 1 to 4 were 
 
 
defined as 'mild', 4 to 7 as ‘moderate’, and a score of 8 or higher was defined as ‘severe’ 
pruritus. Patient characteristics, including maternal age, gravidity, parity, gestational age at 
the time of diagnosis, type of delivery, birth weight of neonates, and length of neonatal 
intensive care unit stay were recorded from patient files. The study protocol was approved by 
the Research Ethics Committee of Kanuni Sultan Suleyman Training and Research Hospital. 
All research procedures were conducted based on the ethical standards of the Declaration of 
Helsinki. Written and verbal informed consent was obtained from participating women prior 
to participation and sampling.  
Blood samples were collected from all participants during the third trimester (at the 
time of initial admission) before the administration of medications or interventions. 
Hemogram (complete blood count) and routine blood biochemistry values were examined 
within one hour after sampling. For further analysis of OST-α, OST-β and NTCP, extracted 
serum samples (centrifuged at 4°C and 3000 RPM for 10 minutes) were frozen at –80°C until 
measurements. Hemogram parameters, including white blood cell count (WBC), neutrophil 
(NEU) and lymphocyte (LYM) counts, hemoglobin value (Hb), platelet count (PLT), mean 
platelet volume (MPV) were measured with a CELL‐ DYN 3700 System (Abbott 
Laboratories, IL, USA). Neutrophil to lymphocyte ratio (NLR) and Platelet to lymphocyte 
ratio (PLR) were calculated. Blood biochemistry parameters, including alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, direct bilirubin and 
TBA levels were determined with spectrophotometric methods using an Abbott Architect 
c8000 autoanalyzer (Abbott Laboratories, IL, USA). The serum OST-α and OST-β levels 
were measured using enzyme-linked immunosorbent assay (ELISA) kits (Elabscience 
Biotechnology, USA) as per the manufacturer’s instructions. The serum NTCP concentrations 
were determined with a commercially available Human Sodium Bile Acid 
Cotransporter/NTCP ELISA Kit (Abbexa Ltd, Cambridge, UK). The measurement range was 
0.78–50 ng/mL and the assay sensitivity was < 0.29 ng/mL. The intra-assay and inter-assay 
variations were < 10% and < 12%, respectively.  
 
Statistical analysis 
All analyses were performed on SPSS v21 (SPSS Inc., Chicago, IL, USA). For the 
normality check, the Kolmogorov-Smirnov test with Lilliefors correction was used. Data are 
given as mean ± standard deviation or median (1st quartile–3rd quartile) for continuous 
variables according to normality of distribution, and as frequency (percentage) for categorical 
variables. Normally distributed variables were analyzed with the independent samples t test. 
 
 
Non-normally distributed variables were analyzed with the Mann Whitney U test. Categorical 
variable distributions were analyzed with Chi-square tests. Repeated (paired) measurements 
were analyzed with the Wilcoxon signed ranks test. Spearman correlation coefficients were 
calculated to evaluate relationships between continuous variables. Diagnostic performance of 
variables were evaluated by Receiver Operating Characteristic (ROC) curve analysis. p < 0.05 
values were defined as statistically significant. 
 
RESULTS 
Sixty-nine patients with ICP and 50 healthy women were included in the study. The 
mean age was 29.8 ± 5.8 years in the study group and 29 ± 5.7 years in the control group (p = 
0.468). The serum levels of ALT, AST, total and direct bilirubin were higher in the patient 
group (all, p < 0.05). Elevated serum levels of hemoglobin, platelet count and PLR were 
found in patients with ICP compared to control subjects (all, p < 0.05). No differences were 
found between the two groups with regard to WBC, MPV, RDW, NLR, neutrophil and 
lymphocyte counts (all, p > 0.05). Demographic characteristics and laboratory values of the 
patient and the control groups are shown in Table 1.  
The median OST-α levels were 176.32 pg/mL in women with ICP and 201.03 pg/mL 
in healthy subjects (p = 0.205). Median OST-β levels were found to be significantly higher 
(51.17 pg/mL) in patients with ICP compared to controls (40.90 pg/mL) (p = 0.033). The 
median NTCP values were 519.71 ng/mL in the ICP and 483.34 (ng/mL) in the healthy 
control group (p = 0.051) (Tab. 1). ROC analysis demonstrated that OST-β levels had 53.62% 
sensitivity, 73.47% specificity and 61.86% accuracy to determine presence of ICP with a cut-
off point of 50.5 (AUC = 0.616, 95% CI: 0.513–0.718) (data not shown). 
The median TBA levels were 26 (16-48) μmol/L in the patient group. According to 
TBA levels, 45 patients had mild ICP and 24 patients had severe ICP. Forty patients received 
4 doses of ursodeoxycholic acid (UDCA) treatment, while 26 patients were treated with 3 
doses. Following the administration of UDCA, 45 patients had reduction in pruritus 
complaints and 34 patients showed decreased ALT and AST levels. After deliveries, 17 of the 
neonates were admitted to the neonatal ICU (Tab. 2). 
Correlation analyses between patient characteristics and laboratory results are shown 
in Table 3. In correlation analyses, we found negative correlations between maternal age and 
the levels of OST-α and NTCP. A positive correlation was shown between NTCP and total 





This study was aimed at determining circulating levels of OST-α, OST-β and NTCP in 
patients with ICP order to identify whether these measures could be utilized to diagnose ICP, 
determine prognosis, or assess fetal outcomes. This was the first study to determine the serum 
levels of OST-α, OST-β and NTCP in patient with ICP. We demonstrated that serum OST-β 
levels were significantly higher in patients with ICP compared to healthy individuals. We also 
observed higher NTCP levels in patients, but statistical significance was not present with a p 
value of 0.051.  
Intrahepatic cholestasis of pregnancy has a complex and multifaceted etiology, 
involving complex interactions between genetic features, endocrine and metabolic 
disturbances, and environmental factors [4]. Altered secretion and transport of bile acids and 
other biliary lipids play an important role on the etiology of ICP [9]. Bile salts are the most 
common organic solutes in the bile [1]. Bile acids (cholic acid and chenodeoxycholic acid) 
are synthesized from cholesterol in the liver, conjugated with either taurine or glycine to form 
bile salts, and are exported into the biliary canaliculi via specific transport proteins [10]. 
When the bile acids reach the gastrointestinal tract, they maintain their emulsifying functions 
as physiological detergents to break down and encapsulate lipids and fat-soluble vitamins for 
absorption and transport. Bile acids are also metabolic signaling molecules with systemic 
endocrine effects [11]. The specific nuclear receptors of bile acids include, farnesoid X 
receptor (FXR), vitamin D receptor, and the cell surface G protein-coupled bile acid receptor 
(GPBAR, TGR-5) [12]. After contributing to intestinal digestion and absorption, bile acids 
are actively transported into intestinal cells in the terminal ileum. The transporters involved in 
this function include OST-α and OST-β [12] which transport the bile acids across the 
basolateral membrane of the enterocytes, followed by secretion into the portal circulation. 
They are actively transported back to hepatocytes via NTCP and organic anion transporting 
polypeptides [10]. The mutations and variations in genes encoding hepatobiliary transport 
proteins have been shown to cause abnormal bile secretion and increased circulatory bile 
acids in patient with ICP [13].  
The OST-α and OST-β heteromeric transport proteins are present in ileal enterocytes, 
cholangiocytes and the renal proximal tubule [14]. FXR mechanisms have been associated 
with the key regulatory roles of OST-α and OST-β in maintaining homeostasis of bile acids 
[15]. As such, intestinal FXR induces the expression of OST-α and OST-β as an adaptive 
response to cholestasis [12]. Boyer et al. demonstrated that hepatic OST-α and OST-β mRNA 
levels were elevated by three-fold and 32-fold, respectively, in patients with primary biliary 
 
 
cirrhosis (PBC). They also demonstrated that OST-α and OST-β expression increased in the 
livers of rats and mice following common bile duct ligation [16]. In another study, Schaap et 
al. [17], showed increased OST-α and OST-β mRNA levels in the livers of patients with 
extrahepatic cholestasis. Malinen and colleagues [18] identified significantly increased 
expression and protein levels of OST-β in livers from patients with nonalcoholic 
steatohepatitis (NASH) and PBC. They also observed unchanged OST-α mRNA expression 
and higher OST-α protein levels in patients with NASH and PBC when compared to healthy 
subjects (but statistical significance was not present). Chai et al. [19], revealed in 22 liver 
samples from cholestatic patients with biliary obstruction (due to gallstones) that mRNA and 
protein levels of OST-β protein levels was significantly increased (10.4 fold), while OST-
α protein levels were decreased while transcription was unchanged compared to control livers. 
Soroka and colleagues [20] demonstrated in mice with genetically deficient OST-α that loss 
of OST-α prevents liver damage in obstructive cholestasis through adaptive responses in both 
the kidney and liver. In agreement with these studies, we found significantly elevated serum 
OST-β levels and somewhat decreased OST-α level (no statistical significance) in patients 
with ICP. Our results may suggest that OST-α and OST-β are induced in ICP, possibly due 
their association with the re-uptake of bile acids. The increase in OST-β levels may be related 
to the elevation of intrahepatic bile acid and TBA concentrations during cholestasis. Further 
studies are necessary to determine whether serum levels of OST-β can be used as a marker for 
the diagnosis and prognostic assessment of ICP. We demonstrated a cut-off point of > 50.5 
for the identification of ICP with OST-β levels. Our results suggest that OST-α and OST-β 
could be contributing factors in the pathogenesis of ICP. However, there is still uncertainty 
about the contribution of OST-α and OST-β to bile acid efflux and attenuation of cholestasis 
in literature [21].  
NTCP is a sodium-dependent primary transporter that transports conjugated bile salts 
from the plasma to the hepatocyte. NTCP is highly expressed in the basolateral membrane of 
hepatocytes and plays an important role in the maintenance of enterohepatic circulation of bile 
salts [7]. Vaz et al. [22], demonstrated mild hypotonia, growth retardation, and elevated total 
bile acid levels (> 1500 µM) without signs of cholestatic jaundice, pruritus, or liver 
dysfunction in a patient with NTCP deficiency caused by a point mutation in the 
SLC10A1 gene. Kojima et al. [23], showed no change in NTCP expression in patients with 
chronic hepatitis C or primary biliary cirrhosis stage I and II, while they identified 
downregulation in stage III. A case reported by Van Herpe et al[24]., described a woman with 
ICP who had lost her fetus at 38 weeks of pregnancy due to spontaneous rupture of 
 
 
membranes with meconium-stained fluids. They revealed persistently elevated TBA levels 
and NTCP deficiency in the post-partum period. In another clinical study, Chen et al. [7], 
demonstrated elevated TBA levels in five patients with NTCP deficiency diagnosed with 
SLC10A1 gene analysis. They also showed that two of these individuals had suffered from 
ICP without intense pruritus in the third trimester of pregnancy — leading to caesarean 
section delivery in one. In our study, we found higher NTCP levels in the ICP group 
compared to controls, a result which was only marginally insignificant (p = 0.051). This 
indicates that elevated NTCP levels may be associated with increased bile acid uptake into the 
liver in ICP disease. Furthermore, NTCP was correlated with age and total bilirubin levels. 
Consistent with our findings, Sargiacomo et al. [25], found that NTCP protein levels were 
modulated in an age-dependent manner in the hepatocyte membrane. In addition, Shneider et 
al. [26], demonstrated that NTCP mRNA levels correlated inversely with serum bilirubin in 
patients with pre- and postportoenterostomy biliary atresia. A mild increase in bilirubin levels 
in ICP patients can lead to increased levels of transport protein for hepatic uptake, and thus 
the excretion of bile salts and bilirubin. 
Several limitations of the current work should be mentioned. First, the study had a 
relatively small sample size which may have reduced statistical strength; thus future studies 
will benefit from utilizing the results of this study in their power analyses. Secondly, the study 
was limited to Turkish ICP patients; considering the known genetic and environmental 
variations in the characteristics of patients with ICP, our results may not be generalized for 
women in other geographic regions. Thirdly, we were not able to evaluate fetal cord levels or 
placental levels of these biomarkers. Lastly, the lack of mRNA expression measurements may 
also be considered as a limitation. 
 
CONSLUSIONS 
In conclusion, this is the first study to evaluate serum levels of OST-α, OST-β and 
NTCP in patients with ICP. We demonstrated significantly elevated OST-β levels in patients 
with ICP. We believe that OST-β and NTCP could contribute to the etiopathogenesis of ICP. 
Early identification and management of ICP prevents adverse outcomes, especially for the 
fetus. It is crucial to determine whether serum levels of OST-α, OST-β or NTCP can be used 
as diagnostic or monitoring markers. Furthermore, considering their role in bile acid turnover, 
it may be interesting to evaluate the inhibition of these transporters as a possible therapeutic 
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Table 1. Participants’ demographic characteristics and laboratory results 
 Controls (n = 50) Patients (n = 69) p value 
Age [years] 29.82 ± 5.81 29.04 ± 5.70 0.468 
Gestational week 28 (24–35) 33 (31–35) 0.013 
Numbers of pregnancy   
 1 10 (20.00%) 21 (30.43%) 
0.372 
 2 13 (26.00%) 21 (30.43%) 
 3 14 (28.00%) 12 (17.39%) 
 ≥ 4 13 (26.00%) 15 (21.74%) 
ALT [IU/mL] 9 (8–13) 72 (48–152.5) < 0.001 
AST [IU/mL] 14.5 (13–17) 55 (35–91) < 0.001 
Total bilirubin [mg/dL] 0.22 (0.16–0.30) 0.49 (0.32–0.73) < 0.001 
Direct bilirubin 
[mg/dL] 
0.11 (0.10–0.12) 0.27 (0.18–0.50) < 0.001 
WBC [× 103/mm3] 9.09 ± 2.57 9.49 ± 1.89 0.327 
Hemoglobin [g/dL] 11.15 ± 1.13 11.66 ± 1.31 0.030 
MPV [µm3] 10.85 (10.1–11.9) 11.15 (10.2–11.7) 0.618 
RDW [%] 13.25 (13–13.7) 13.1 (12.6–13.8) 0.494 
Neutrophil [× 103/mm3] 7.79 (6.39–8.4) 7 (5.3–7.8) 0.054 
Lymphocyte [× 
103/mm3] 
1.9 (1.7–2.3) 1.8 (1.6–2) 0.051 
Platelet [× 103/mm3] 214.04 ± 47.58 245.87 ± 74.17 0.005 
NLR 3.85 (3.18–4.51) 3.91 (2.83–4.68) 0.907 
PLR 114.45 (91.58–131.30) 124.41 (108.23–176.03) 0.006 
OST-alpha [pg/mL] 201.03 (167.01–238.36) 176.32 (145.76–212.27) 0.205 
OST-beta [pg/mL] 40.90 (30.62–51.16) 51.17 (36.44–62.42) 0.033 
NTCP [ng/mL] 483.34 (98.23–601.82) 519.71 (416.58–677.62) 0.051 
ALT — Alanine aminotransferase; AST — Aspartate aminotransferase; WBC — White 
blood cell counts; MPV — Mean platelet volume; NLR — Neutrophil to lymphocyte ratio; 
PLR — Platelet to lymphocyte ratio; OST-alpha — Organic solute transporter alpha; OST-
beta — Organic solute transporter beta; NTCP — Sodium taurocholate cotransporting 
polypeptide; Data are given as mean ± standard deviation or median (1st quartile–3rd quartile) 
 
 
for continuous variables according to normality of distribution and as frequency (percentage) 
for categorical variables 
 
Table 2. Patients’ characteristics and laboratory results 
Total Bile acid [μmol/L] 26 (16–48) 
Patients with mild ICP [< 40] 45 (65.22%) 
Patients with severe ICP [≥ 40] 24 (34.78%) 
UDCA 4 (3–4) 
0 1 (1.45%) 
2 1 (1.45%) 
3 26 (37.68%) 
4 40 (57.97%) 
6 1 (1.45%) 
Pruritus  
Mild 25 (37.68%) 
Moderate 19 (27.54%) 
Severe 24 (34.78%) 
Decrease in pruritus after UDCA 45 (77.59%) 
Decrease in ALT after UDCA 34 (73.91%) 
Decrease in AST after UDCA 34 (72.34%) 
Alkaline phosphotase [IU/L] 199.27 ± 71.43 
Gamma glutamyl transferase [IU/L] 17 (11–29) 
Lactate dehydrogenase [IU/L] 227.22 ± 49.25 
Gestational week at birth 37 (36–38) 
Birth type  
Vaginal 22 (37.93%) 
Cesarean 36 (62.07%) 
Weight at birth [grams] 2793.17 ± 581.35 
The number of patients requiring ICU admission 17 (29.31%) 
ICP — INntrahepatic cholestasis of pregnancy; UDCA — Ursodeoxycholic acid; ICU — 
Intensive care unit; Data are given as mean ± standard deviation or median (1st quartile–3rd 
quartile) for continuous variables according to normality of distribution and as frequency 




Table 3. Correlations between clinical and laboratory characteristics in intrahepatic 
cholestasis of pregnancy patients 
    OST-alpha OST-beta NTCP 
Age 
  
r –0.278* –0.169 –0.277* 
p 0.002 0.067 0.002 
Gestational week 
  
r 0.056 –0.105 0.065 
p 0.548 0.259 0.483 
Total Bile acid 
  
r –0.177 –0.099 –0.107 
p 0.145 0.417 0.381 
ALT 
  
r –0.150 0.144 0.133 
p 0.106 0.121 0.152 
AST 
  
r –0.117 0.145 0.115 
p 0.213 0.120 0.218 
Total bilirubin 
  
r –0.058 0.068 0.236* 
p 0.540 0.472 0.012 
Direct bilirubin 
  
r –0.045 0.182 0.156 
p 0.632 0.052 0.098 
Alkaline 
phosphatase 
r 0.168 –0.056 0.028 
p 0.203 0.673 0.831 
Gamma-glutamyl  
 transferase 
r 0.024 –0.020 –0.006 
p 0.858 0.878 0.961 
Lactate  
 Dehydrogenase 
r 0.238 –0.100 0.053 
p 0.083 0.471 0.703 
WBC 
  
r 0.102 0.128 0.063 
p 0.274 0.169 0.503 
Hemoglobin 
 value 
r –0.033 0.130 0.150 
p 0.724 0.163 0.107 
MPV 
  
r –0.107 –0.033 0.090 
p 0.250 0.728 0.332 
RDW 
  
r 0.010 –0.077 –0.011 
p 0.911 0.408 0.909 
Neutrophil 
counts  
r –0.005 0.076 0.105 





r 0.010 0.041 0.010 
p 0.916 0.659 0.918 
Platelet 
 count 
r –0.027 0.177 –0.059 
p 0.774 0.057 0.527 
NLR 
  
r –0.012 0.044 0.125 
p 0.899 0.641 0.181 
PLR 
  
r –0.018 0.124 –0.056 
p 0.845 0.181 0.547 
ALT — Alanine aminotransferase; AST — Aspartate aminotransferase; WBC — White 
blood cell counts; MPV — Mean platelet volume; NLR — Neutrophil to lymphocyte ratio; 
PLR — Platelet to lymphocyte ratio; OST-alpha — Organic solute transporter alpha; OST-
beta — Organic solute transporter beta; NTCP — Sodium taurocholate cotransporting 
polypeptid. r — Spearman correlation coefficient; * Correlation is significant at the 0.05 level 
